Anticholinergics

theoretical and clinical overview

Prasad S. Nishtala, Mohammed Saji Salahudeen, Sarah N. Hilmer

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Introduction: Anticholinergics are a class of medicines that block the neurotransmitter, acetylcholine, in the brain and peripheral tissues. Medicines with anticholinergic activity are widely prescribed for and used by older people for various medical conditions. One-third to one-half of the medicines commonly prescribed for older people have anticholinergic activity. Several studies have reported anticholinergic burden to be a predictor of cognitive and functional impairments in older people. Areas covered: This article exemplifies the theoretical and clinical aspects of medicines with anticholinergic activity, including pharmacology (definition of medicines that possess anticholinergic activity, antimuscarinic receptors, therapeutic and adverse effects), epidemiology, measures and effects of cumulative anticholinergic burden in older adults, and clinical recommendations. In addition, the gaps in the literature have been identified for future research. Expert opinion: Many medicines that are commonly prescribed to older people have a degree of anticholinergic activity that can contribute to anticholinergic burden. Anticholinergic burden, measured in several ways that consider number, dose and/or degree of anticholinergic activity of medicines, has shown to be a predictor of adverse health and functional outcomes. The anticholinergic burden on older people should be minimised by avoiding, reducing dose and deprescribing medicines with anticholinergic activity where clinically possible.

Original languageEnglish
Pages (from-to)753-768
Number of pages16
JournalExpert Opinion on Drug Safety
Volume15
Issue number6
Early online date30 Mar 2016
DOIs
Publication statusPublished - 2 Jun 2016

Fingerprint

Cholinergic Antagonists
Muscarinic Antagonists
Clinical Medicine
Expert Testimony
Therapeutic Uses
Acetylcholine
Neurotransmitter Agents
Epidemiology
Pharmacology

Keywords

  • acetylcholine
  • Anticholinergic
  • anticholinergic activity
  • anticholinergic adverse effect
  • anticholinergic burden
  • anticholinergic mechanism
  • anticholinergic medicine
  • anticholinergic overview
  • anticholinergic risk scale
  • antimuscarinic
  • muscarinic receptor
  • older people

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Anticholinergics : theoretical and clinical overview. / Nishtala, Prasad S.; Salahudeen, Mohammed Saji; Hilmer, Sarah N.

In: Expert Opinion on Drug Safety, Vol. 15, No. 6, 02.06.2016, p. 753-768.

Research output: Contribution to journalReview article

Nishtala, Prasad S. ; Salahudeen, Mohammed Saji ; Hilmer, Sarah N. / Anticholinergics : theoretical and clinical overview. In: Expert Opinion on Drug Safety. 2016 ; Vol. 15, No. 6. pp. 753-768.
@article{10d38c663de9492e9166886dda8f6007,
title = "Anticholinergics: theoretical and clinical overview",
abstract = "Introduction: Anticholinergics are a class of medicines that block the neurotransmitter, acetylcholine, in the brain and peripheral tissues. Medicines with anticholinergic activity are widely prescribed for and used by older people for various medical conditions. One-third to one-half of the medicines commonly prescribed for older people have anticholinergic activity. Several studies have reported anticholinergic burden to be a predictor of cognitive and functional impairments in older people. Areas covered: This article exemplifies the theoretical and clinical aspects of medicines with anticholinergic activity, including pharmacology (definition of medicines that possess anticholinergic activity, antimuscarinic receptors, therapeutic and adverse effects), epidemiology, measures and effects of cumulative anticholinergic burden in older adults, and clinical recommendations. In addition, the gaps in the literature have been identified for future research. Expert opinion: Many medicines that are commonly prescribed to older people have a degree of anticholinergic activity that can contribute to anticholinergic burden. Anticholinergic burden, measured in several ways that consider number, dose and/or degree of anticholinergic activity of medicines, has shown to be a predictor of adverse health and functional outcomes. The anticholinergic burden on older people should be minimised by avoiding, reducing dose and deprescribing medicines with anticholinergic activity where clinically possible.",
keywords = "acetylcholine, Anticholinergic, anticholinergic activity, anticholinergic adverse effect, anticholinergic burden, anticholinergic mechanism, anticholinergic medicine, anticholinergic overview, anticholinergic risk scale, antimuscarinic, muscarinic receptor, older people",
author = "Nishtala, {Prasad S.} and Salahudeen, {Mohammed Saji} and Hilmer, {Sarah N.}",
year = "2016",
month = "6",
day = "2",
doi = "10.1517/14740338.2016.1165664",
language = "English",
volume = "15",
pages = "753--768",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis",
number = "6",

}

TY - JOUR

T1 - Anticholinergics

T2 - theoretical and clinical overview

AU - Nishtala, Prasad S.

AU - Salahudeen, Mohammed Saji

AU - Hilmer, Sarah N.

PY - 2016/6/2

Y1 - 2016/6/2

N2 - Introduction: Anticholinergics are a class of medicines that block the neurotransmitter, acetylcholine, in the brain and peripheral tissues. Medicines with anticholinergic activity are widely prescribed for and used by older people for various medical conditions. One-third to one-half of the medicines commonly prescribed for older people have anticholinergic activity. Several studies have reported anticholinergic burden to be a predictor of cognitive and functional impairments in older people. Areas covered: This article exemplifies the theoretical and clinical aspects of medicines with anticholinergic activity, including pharmacology (definition of medicines that possess anticholinergic activity, antimuscarinic receptors, therapeutic and adverse effects), epidemiology, measures and effects of cumulative anticholinergic burden in older adults, and clinical recommendations. In addition, the gaps in the literature have been identified for future research. Expert opinion: Many medicines that are commonly prescribed to older people have a degree of anticholinergic activity that can contribute to anticholinergic burden. Anticholinergic burden, measured in several ways that consider number, dose and/or degree of anticholinergic activity of medicines, has shown to be a predictor of adverse health and functional outcomes. The anticholinergic burden on older people should be minimised by avoiding, reducing dose and deprescribing medicines with anticholinergic activity where clinically possible.

AB - Introduction: Anticholinergics are a class of medicines that block the neurotransmitter, acetylcholine, in the brain and peripheral tissues. Medicines with anticholinergic activity are widely prescribed for and used by older people for various medical conditions. One-third to one-half of the medicines commonly prescribed for older people have anticholinergic activity. Several studies have reported anticholinergic burden to be a predictor of cognitive and functional impairments in older people. Areas covered: This article exemplifies the theoretical and clinical aspects of medicines with anticholinergic activity, including pharmacology (definition of medicines that possess anticholinergic activity, antimuscarinic receptors, therapeutic and adverse effects), epidemiology, measures and effects of cumulative anticholinergic burden in older adults, and clinical recommendations. In addition, the gaps in the literature have been identified for future research. Expert opinion: Many medicines that are commonly prescribed to older people have a degree of anticholinergic activity that can contribute to anticholinergic burden. Anticholinergic burden, measured in several ways that consider number, dose and/or degree of anticholinergic activity of medicines, has shown to be a predictor of adverse health and functional outcomes. The anticholinergic burden on older people should be minimised by avoiding, reducing dose and deprescribing medicines with anticholinergic activity where clinically possible.

KW - acetylcholine

KW - Anticholinergic

KW - anticholinergic activity

KW - anticholinergic adverse effect

KW - anticholinergic burden

KW - anticholinergic mechanism

KW - anticholinergic medicine

KW - anticholinergic overview

KW - anticholinergic risk scale

KW - antimuscarinic

KW - muscarinic receptor

KW - older people

UR - http://www.scopus.com/inward/record.url?scp=84961964236&partnerID=8YFLogxK

U2 - 10.1517/14740338.2016.1165664

DO - 10.1517/14740338.2016.1165664

M3 - Review article

VL - 15

SP - 753

EP - 768

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 6

ER -